Seattle’s SEngine Precision Medicine has raised $10M in a new funding round led by The Washington Research Foundation.
The new capital will be used to hire employees, expand lab space and explore new partnerships. SEngine is working on the “PARIS” test in which cancer treatments are tested for effectiveness outside of patients’ bodies, on live tumor cells. The testing creates drug sensitivity reports for multiple cancers, including colon, breast, lung, ovarian and pancreatic.
“We are very appreciative of our investors’ support and their recognition of the need for more and better personalized treatments,” said SEngine CEO Carla Grandori. “The company’s work has the power to improve patient outcomes by providing oncologists individual drug effectiveness rankings as well as the innovation of new drugs.”